Although valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is an effective treatment of TD, it may induce drug‐induced parkinsonism (DIP) in some patients. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.